Cowen & Co.
TD Cowen, JP Morgan Initiate Coverage of Tempus AI With Buy, Overweight Ratings
Cowen said that Tempus is a differentiated oncology diagnostics company with an order backlog from pharma clients and the potential for strong growth and rising margins.
TD Cowen Downgrades Illumina to Market Perform
The consensus Wall Street estimate for 2024 revenues suggests no growth, analyst Dan Brennan noted, though better margins could help sales rebound in 2025.
TD Cowen Initiates Coverage of MDxHealth With Outperform Rating
Analyst Dan Brennan wrote in a note to investors that the company's position in an under-penetrated market bodes well for future revenue growth.
TD Cowen Upgrades Shares of Pacific Biosciences to Outperform
A survey revealed that labs with multiple PacBio Sequel instruments plan to buy an average of three Revio sequencers each, TD Cowen Analyst Dan Brennan said.
Pacific Biosciences to Raise $175M in Public Stock Offering
The company is selling 17.5 million shares of its common stock at a price of $10 per share in the offering, which is expected to close Jan. 27.